

IPCR - Contributions for ISAA report no. 58 on COVID-19 - Questions**1. Questionnaire 1 - Public health****1.1. Epidemiology****1.1.1. Question**

Q1: Please indicate your nationally estimated basic reproduction number (R0).

R(t) = 1.11 based on data from march 8th

Expected type of value : Text of maximum 1500 characters.

**1.1.2. Question**

Q2: Please indicate your nationally estimated relative contribution of reduction of reproduction (R) and/or contact rate by measure (if known).

Unknown

Expected type of value : Text of maximum 1500 characters.

**1.1.3. Question**

Q3: Please indicate the % of symptomatic vs asymptomatic.

It is problematic to differentiate between symptomatic and asymptomatic patients in The Netherlands. Not all (a) symptomatic patients are recorded or tested.

Expected type of value : Text of maximum 1500 characters.

**1.1.4. Question**

Q4: Please indicate the % of symptomatic requiring hospitalization.

25747 hospitalizations out of 1213366 confirmed COVID cases = 2.1%

Expected type of value : Text of maximum 1500 characters.

**1.1.5. Question**

Q5: Please indicate the % of hospitalized requiring intensive / critical care.

643 IC patients out of 2238 hospitalized patients on March 28 = 58,72%

Expected type of value : Text of maximum 1500 characters.



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



### 1.1.6. Question

Q6: Please indicate the infection fatality rate.

The Dutch Institute for Public Health & the Environment (RIVM) currently estimates the IFR at about 1,3%

Expected type of value : Text of maximum 1500 characters.

### 1.1.7. Question

Q7: Please indicate the prevalence of symptomatic cases.

This is not known because the denominator is not known.

Expected type of value : Text of maximum 1500 characters.

### 1.1.8. Question

Q8: Please indicate the attack rate.

This is not known because the denominator is not known.

Expected type of value : Text of maximum 1500 characters.

### 1.1.9. Question

Q9: Please indicate, if available, the % of immunity achieved.

Unknown

Expected type of value : Text of maximum 1500 characters.

### 1.1.10. Question

Q10: Please indicate what values should the parameters above have, as criteria for lifting of physical distancing measures, public spaces and schools re-opening as well as re-introduction of mass-gatherings, lifting of travel restrictions and re-opening of borders.

The Dutch government applies 4 risk levels: cautious, worrisome, serious, very serious.

The risk level of a region depends on the number of positive tests and hospital admissions (including IC).

Expected type of value : Text of maximum 1500 characters.

## 1.2. Resources shortfalls in response

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)





<b>1.2.1. Question</b>	
Q11: Is a stockpile of PPE in place at national level?	
<input checked="" type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	Please specify:
Free text for Option n° 3	

<b>1.2.2. Question</b>	
Q12: Is your country facing shortages of any of the below mentioned items?	
<input type="checkbox"/>	Ventilators / respirators
<input type="checkbox"/>	Personal protective equipment (Masks, gowns, goggles)
<input type="checkbox"/>	COVID-19 Testing kits
<input type="checkbox"/>	Reagents
<input type="checkbox"/>	Medicines (e.g. paracetamol...)
<input type="checkbox"/>	Disinfectants
<input type="checkbox"/>	Other
Free text for Option n° 7	

<b>1.2.3. Question</b>	
Q13: Is your country planning / conducting national procurement procedures for any of the below mentioned items?	
<input type="checkbox"/>	Ventilators / Respirators
<input type="checkbox"/>	Personal protective equipment (masks, gowns, goggles)
<input type="checkbox"/>	COVID-19 testing kits
<input type="checkbox"/>	Reagents
<input type="checkbox"/>	Medicines (e.g. paracetamol...)
<input type="checkbox"/>	Disinfectants
<input type="checkbox"/>	Other:
Free text for Option n° 7	





<b>1.2.4. Question</b>	
Q14: Do you expect shortages of medical gloves in the next month?	
<input type="checkbox"/>	YES
<input checked="" type="checkbox"/>	NO

<b>1.2.5. Question</b>	
Q15: Do you expect shortages of medical gloves in the next three months?	
<input type="checkbox"/>	YES
<input type="checkbox"/>	NO

<b>1.2.6. Question</b>	
Q16: In case of expected shortages, can you quantify (range/order of magnitude)	
Expected type of value : Text of maximum 1500 characters.	

<b>1.2.7. Question</b>	
Q17: In case of expected shortages, which measures are you taking/considering?	
Expected type of value : Text of maximum 1500 characters.	

### 1.3. Testing strategy

<b>1.3.1. Question</b>	
Q18: What testing strategy is currently in place in your country? Testing of...?	
<input type="checkbox"/>	Symptomatic but prioritising specific groups (e.g. patients, elderly, vulnerable, HCW)
<input checked="" type="checkbox"/>	All symptomatic people
<input checked="" type="checkbox"/>	Asymptomatic within certain groups or settings (e.g. contact tracing, outbreak clusters, healthcare settings, specific professional groups, nursing homes)
<input type="checkbox"/>	All asymptomatic people (mass testing)
<input checked="" type="checkbox"/>	Asymptomatic people for epidemiological surveillance
<input checked="" type="checkbox"/>	Close contacts
<input checked="" type="checkbox"/>	Please specify:
Free text for Option n° 7	
As of the 1st of december the NL additionally tests asymptomatic cases through our contact tracing mobile application and close contacts that are being found through contact tracing (on 1st an the 5th day after contact with an positive-tested person) Since the beginning of january asymptomatic people are tested for	





<b>1.3.2. Question</b>
Q19: Which approach is used with regards to asymptomatic testing?
Since the first of december, asymptomatic persons that have been identified as close contacts and close contacts that are being found through CoronaMelder (a contact tracing app) can get tested on the first and 5th day of quarantaine. In case the test is negative, quarantaine can be ended. Since january 20th all incoming
Expected type of value : Text of maximum 1500 characters.

<b>1.3.3. Question</b>
Q20: Are you currently using rapid tests or antibody tests?
<input checked="" type="checkbox"/> Yes, antigen tests
<input type="checkbox"/> Yes, antibody
<input type="checkbox"/> No
<input type="checkbox"/> Please specify:
Free text for Option n° 4

<b>1.3.4. Question</b>
Q21: If antigen test is used, are results accepted as basis for public health measures (e.g. quarantine)?
Yes. Antigen test results are accepted as basis for measures for symptomatic persons. For asymptomatic persons that have been identified as close contacts and persons that have been identified via contact tracing mobile applications need to be tested for the time being with a PCR test (on the 5th day of quarantine.) In case
Expected type of value : Text of maximum 1500 characters.

<b>1.3.5. Question</b>
Q22: Do you experience challenges related to the willingness to get tested among the general population or certain population groups?
At this moment, no signals of challenges related to willingness to get tested have been reported.
Expected type of value : Text of maximum 1500 characters.

<b>1.3.6. Question</b>
Q23: What is the current testing Turn Around Time (TAT: time between the test request and the receipt of test results by the health professional)?
<input type="checkbox"/> Within 24 h
<input checked="" type="checkbox"/> Within 48 h
<input type="checkbox"/> More than 48 h

<b>1.3.7. Testing of incoming travellers</b>
--



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



1.3.7.1. Question	
Q24: In case a negative test upon entry is required, which type of test result is accepted?	
<input checked="" type="checkbox"/>	RT-PCR
<input checked="" type="checkbox"/>	Rapid antigen test
<input type="checkbox"/>	N/A
<input checked="" type="checkbox"/>	Other, please specify
Free text for Option n° 4	
Travellers have to have a negative PCR-test taken within 72 hours before departure and have to have a negative rapid antigen test taken within 8 hours before departure.	

1.3.7.2. Question	
Q25: Do you experience any problems with the mutual recognition of COVID-19 test results of incoming travellers?	
<input checked="" type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input checked="" type="checkbox"/>	Other, please specify
Free text for Option n° 3	
A negative antibody test is not recognized for incoming travellers.	

1.3.7.3. Question	
Q26: Can incoming travellers be tested upon arrival at the airport, and if so, what type of testing is offered?	
<input checked="" type="checkbox"/>	No
<input type="checkbox"/>	Yes, mandatory RT-PCR test
<input type="checkbox"/>	Yes, voluntary RT-PCR test
<input type="checkbox"/>	Yes, mandatory rapid antigen test
<input type="checkbox"/>	Yes, voluntary rapid antigen test
<input type="checkbox"/>	Other, please specify
Free text for Option n° 6	

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



1.3.7.4. Question	
Q27: Following a negative test result, can the self-quarantine period for incoming travellers be shortened or cancelled? If yes, please specify.	
<input checked="" type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	N/A
<input checked="" type="checkbox"/>	Please specify
Free text for Option n° 4	
Since January 20th all travellers can get tested on the 5th day of quarantine. In case the test is negative, quarantine can be ended.	

1.3.7.5. Question	
Q28: Do you require incoming travellers to complete a passenger locator form (PLF), and if so, should this form be completed online or on paper?	
<input checked="" type="checkbox"/>	No
<input type="checkbox"/>	Yes, digital PLF
<input type="checkbox"/>	Yes, paper PLF
<input type="checkbox"/>	Other, please specify:
Free text for Option n° 4	

1.3.7.6. Question	
Q29: Do you currently recommend avoiding non-essential travel, in particular to areas with a significantly higher incident of new SARS-CoV-2 variants?	
<input type="checkbox"/>	No
<input checked="" type="checkbox"/>	Yes, we recommend avoiding all non-essential travel in general
<input type="checkbox"/>	Yes, we recommend avoiding non-essential travel to areas with a significantly higher incident of new SARS-CoV-2 variants
<input type="checkbox"/>	Other, please specify
Free text for Option n° 4	

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



### 1.3.7.7. Question

Q30: Do you have specific testing measures and/or quarantine measures in place for travelers coming from areas with significantly higher incidence of new SARS-CoV-2 variants?

- Yes, specific testing measures
- Yes, specific quarantine measures
- Other
- If yes, please specify:

Free text for Option n° 4

### 1.3.7.8. Question

Q31: Have you increased sequencing efforts of samples taken from incoming travelers from areas with significantly higher incidence of new SARS-CoV-2 variants? If yes, please specify.

- Yes
- No
- Please specify

Free text for Option n° 3

In general, we have increased sequencing efforts

## 1.4. Laboratory capacity

### 1.4.1. Question

Q32: How many laboratories are able to test for COVID-19 and how many tests can be performed per day? Please indicate planned scale up in testing capacity.

The available test capacity is over 175.000 COVID-tests per day

Expected type of value : Text of maximum 1500 characters.

### 1.4.2. Question

Q33: How many RT-PCR tests have you performed weekly since the beginning of the outbreak in your country? Please respond indicating number of tests per calendar week.

In the first few weeks that everyone with symptoms could be tested, this started per the 1st of June, till half July, roughly 70.000-140.000 people got tested on a weekly bases.  
week 29: 133.000

Expected type of value : Text of maximum 1500 characters.

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



<b>1.4.3. Question</b>	
Q34: Has your country identified any particular issues with regards to testing capacity? E.g. shortages in testing kits, difficulties to scale up capacities?	
<input checked="" type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input checked="" type="checkbox"/>	Please specify what issues have been identified and what measures have been implemented to address these gaps
Free text for Option n° 3	
We have experienced issues in scaling up the testcapacity and shortages in certain materials. The main solution was to contract foreign laboratories that could perform much larger volumes of tests per day. At the beginning we have also bought multiple machines wich needed different materials in order to prevent shortage.	

<b>1.4.4. Question</b>	
Q35: Has your country identified shortages in lab staff?	
<input type="checkbox"/>	Yes
<input checked="" type="checkbox"/>	No
<input type="checkbox"/>	Please specify what measures have been implemented to address these gaps:
Free text for Option n° 3	

## 1.5. Case management

<b>1.5.1. Question</b>	
Q36: How many Intensive Care Units (ICU) for COVID-19 patients are available in your country?	
Expected type of value : Text of maximum 1500 characters.	

<b>1.5.2. Question</b>	
Q37: What % of Intensive Care Units (ICU) are currently occupied with COVID-19 patients?	
Expected type of value : Text of maximum 1500 characters.	

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



### 1.5.3. Question

Q38: How many additional Intensive care beds can you set up as surge capacity?

Expected type of value : Text of maximum 1500 characters.

### 1.5.4. Question

Q39: What is your country's strategy to isolation / quarantine of contacts / cases after the lifting of measures?

Expected type of value : Text of maximum 1500 characters.

### 1.5.5. Question

Q40: Are you planning to use any unlicensed treatments?

- Yes
- No

### 1.5.6. Question

Q41: If yes, please specify based on the available data, which class of drugs / drug would you prefer to use.

- Monoclonal antibodies
- Interferon
- Veklury (Remdisivir)
- Favipirivir
- Polyclonal antibodies
- Dexamethasone
- Other. Please specify, in particular if monoclonal antibodies:

Free text for Option n° 7

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



1.5.7. Question	
Q42: Are you running tendering procedures of any of these medicines? (not through the Joint Procurement Agreement)	
<input type="checkbox"/>	Monoclonal antibodies
<input type="checkbox"/>	Interferon
<input type="checkbox"/>	Remdesivir
<input type="checkbox"/>	Favipirivir
<input type="checkbox"/>	Polyclonal antibodies
<input type="checkbox"/>	Other. Please specify, in particular if monoclonal antibodies:
Free text for Option n° 6	

1.5.8. Question	
Q43: Are you taking part in any of the following joint procurement procedures?	
<input type="checkbox"/>	ICU Medicines
<input type="checkbox"/>	Veklury/ Remdisivir
<input type="checkbox"/>	Large scale vaccination supplies
<input type="checkbox"/>	Rapid antigen tests
<input type="checkbox"/>	Monoclonal antibodies

1.5.9. Question	
Q44: Has your country identified broader impact on health care provision, e.g. in terms of delay in the provision of non-COVID related healthcare services?	
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	Please specify:
Free text for Option n° 3	

1.5.10. Question	
Q45: What is your country's approach to ensure capacities in other non-COVID related healthcare services?	
Expected type of value : Text of maximum 1500 characters.	

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



### 1.5.11. Question

Q45a: Has there been any disruptions of/delays in childhood vaccination programmes

Expected type of value : Text of maximum 1500 characters.

## 1.6. Research

### 1.6.1. Question

Q46: Are you including cases in clinical trials?

Yes

No

Please specify:

Free text for Option n° 3

## 1.7. Contact tracing:

### 1.7.1. Question

Q47: Does your country have sufficient capacities for extensive contact tracing linked with large scale testing?

Yes

No

Please specify planned scale up of contact tracing capacities:

Free text for Option n° 3

This week our capacity for contact tracing was around 7.900 fte(fulltime-equivalent)

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



<b>1.7.2. Question</b>	
Q48: Has your country witnessed any particular issues in the context of contact tracing? E.g. difficulties to scale up contact tracing, human resources	
<input checked="" type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input checked="" type="checkbox"/>	Please specify:
Free text for Option n° 3	
Infection disease doctors are a bottleneck in the analysis of the data. They can only guarantee the quality of the analysis with a max of 2.000 contact tracing a day. Furthermore, a big increase of positive tested persons can also be detected as a bottleneck. If this number is higher than 3.000 a day, contact tracing can be less effective.	

## 1.8. Vaccination strategies

<b>1.8.1. Question</b>	
Q51: Please state the name/s of COVID-19 vaccine/s currently being rolled-out and the date of first administration of doses (dd.mm.yyyy)	
BioNTech/Pfizer 06-01-2021 Moderna 25-01-2021 AstraZeneca 12-02-2021	
Expected type of value : Text of maximum 1500 characters.	

<b>1.8.2. Question</b>	
Q52: How many phases of prioritisation does your country have?	
4 phases; phase 1 elderly, healthcare staff and people living in elderly care, Intellectaly handicapped in institutions and their staff; People from 60years of age, nurses delivering home based care, people with high risk medical indication	
Expected type of value : Text of maximum 1500 characters.	

<b>1.8.3. Question</b>	
Q53: What phase of prioritisation are you currently in?	
First phase	
Expected type of value : Text of maximum 1500 characters.	

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



1.8.4. Question	
Q54: What groups among the prioritised groups are currently being vaccinated?	
<input checked="" type="checkbox"/>	Elderly based on age-range (please specify below the age-range)
<input checked="" type="checkbox"/>	Elderly in long-term care facilities
<input checked="" type="checkbox"/>	Staff working in long-term care facilities
<input checked="" type="checkbox"/>	Adults with underlying health conditions (please specify age range and the underlying conditions)
<input checked="" type="checkbox"/>	Healthcare workers
<input type="checkbox"/>	Social care workers
<input type="checkbox"/>	Other essential workers critical to societal infrastructure (please specify)
<input type="checkbox"/>	Socially vulnerable groups (please specify)
<input type="checkbox"/>	Adults in different age groups (include age ranges)
<input checked="" type="checkbox"/>	Other groups
<input checked="" type="checkbox"/>	Please specify
Free text for Option n° 11	
Down syndrome age 18+ Morbid obesity (BMI>40) age 18+ - people with an intellectual disability living in institutions	

1.8.5. Question	
Q55: Has your country made adjustments to the original priority groups during the roll-out of the vaccine?	
<input checked="" type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	Currently under discussion
<input checked="" type="checkbox"/>	If yes, please provide details of these adjustments and the reasons for this/these adjustments:
Free text for Option n° 4	
due to COVID-19 care being jeopardy, acute COVID care staff has been vaccinated in hospitals and so have General Practitioners Next to that we defined extra high risk groups with a medical indication	

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)





1.8.6. Question	
Q56: Has your country extended the timing between the first and second dose of authorised vaccines?	
<input checked="" type="checkbox"/>	YES, we have extended the timing to provide the first dose to as many people in the priority groups as possible.
<input type="checkbox"/>	NO, we have not extended the timing between the doses and will give the complete course of doses to the priority groups within the current time schedule outlined in the EMA product information for each EU authorised vaccine.
<input type="checkbox"/>	This is currently under discussion.
<input checked="" type="checkbox"/>	If your country has extended the timing between doses, please provide the vaccine product name and the recommended timing between doses:
Free text for Option n° 4	
Pfizer from 3 week interval to a 6 week interval	

1.8.7. Question	
Q57: Does your country use additional doses from COVID-19 vaccine vials? (e.g. a sixth dose from the 5-dose vial of the BioNTech/Pfizer COVID-19 vaccine Comirnaty)	
<input checked="" type="checkbox"/>	YES
<input type="checkbox"/>	NO
<input type="checkbox"/>	Currently under discussion

1.8.8. Question	
Q58: Has there been any change in vaccination guidelines related to suspected adverse events following immunization? (e.g., advice to doctors that a balance of benefit versus risk of vaccination for very frail patients and terminally ill patients)	
<input type="checkbox"/>	YES
<input type="checkbox"/>	NO
<input checked="" type="checkbox"/>	Currently under discussion
<input type="checkbox"/>	If yes, please explain in more detail the changes in vaccination guidelines:
Free text for Option n° 4	





1.8.9. Question	
Q59: Has there been any change in the vaccination strategy in light of the circulation of the new variants of concern? (e.g. adaption of priority groups; use of one vaccine product for certain target groups, prioritisation of geographical areas where new variants have been circulating)	
<input checked="" type="checkbox"/>	YES
<input type="checkbox"/>	NO
<input type="checkbox"/>	Currently under discussion
<input checked="" type="checkbox"/>	If yes, please specify in more detail the changes in the vaccination strategy:
Free text for Option n° 4	
due to COVID-19 care being jeopardy, acute COVID care staff has been vaccinated in hospitals and so have General Practitioners	

1.8.10. Question	
Q60: Are you currently recommending any vaccine products for particular age groups or target groups? (e.g. Oxford/AstraZeneca vaccine to individuals under 65 years of age or a particular vaccine product for healthcare workers)	
<input checked="" type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	Currently under discussion
<input checked="" type="checkbox"/>	If yes, please explain in more detail the recommendations for different vaccine products for different age categories or target groups:
Free text for Option n° 4	
BioNTech/Pfizer and Moderna (mRNA vaccins) in elderly and immunocompromised patients	

1.8.11. Question	
Q61a: Is your country recommending vaccination to those individuals who have been previously infected with SARS-CoV-2?	
<input type="checkbox"/>	Yes
<input checked="" type="checkbox"/>	Yes, but only one dose of vaccine is recommended (for vaccines that have a two-dose regimen)
<input type="checkbox"/>	No
<input type="checkbox"/>	Currently under discussion



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



<b>1.8.12. Question</b>
Q61b: If only one dose of vaccine is offered to those previously infected, for which vaccine products do you only offer one dose?
AstraZeneca, Moderna and Pfizer
Expected type of value : Text of maximum 1500 characters.
<b>1.8.13. Question</b>
Q61c: If your country is NOT recommending vaccination to those previously infected or is only offering one dose, how long are you verifying documentation of previous infection?
We do not request documentation for verification
Expected type of value : Text of maximum 1500 characters.
<b>1.8.14. Question</b>
Q61d: If your country is NOT recommending vaccination to those previously infected or is only offering one dose, how long since a person has been infected do you recommend vaccination (for example, individuals infected with SARS-CoV-2 in the last three to six months previously are not recommended vaccination)?
Last 6 months
Expected type of value : Text of maximum 1500 characters.
<b>1.8.15. Question</b>
Q61e: If your country is NOT recommending vaccination to those previously infected or is only offering one dose, is there a target group where only one dose or no doses are recommended (e.g. age)?
previously infected last 6 months
Expected type of value : Text of maximum 1500 characters.

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)





<b>1.8.16. Question</b>	
Q62: Is your country planning to issue official vaccination certificates?	
<input checked="" type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input checked="" type="checkbox"/>	If yes, have you started discussions regarding the possible future use of the certificates? (e.g. travel, tourism, easing of non-pharmaceutical interventions, access to specific places/events, etc.):
Free text for Option n° 3	
The Netherlands is currently developing a vaccination certificate to facilitate international travel. There is discussion about future use within the Netherlands for national policies, however first more scientific data is necessary about the effect of vaccination on transmission of the virus	

<b>1.8.17. Question</b>	
Q63: Are you discussing or planning at national level how to consider persons that will enter the country having been vaccinated with a vaccine not authorized in the EU?	
<input type="checkbox"/>	-No, this is currently not an issue as there is very limited evidence available supporting that a person vaccinated against SARS-CoV-2 with any of the currently available vaccines (including those authorised in the EU) is unable to transmit COVID-19
<input type="checkbox"/>	-There is very limited evidence available supporting that a person vaccinated against SARS-CoV-2 with any of the currently available vaccines (including those authorised in the EU) is unable to transmit COVID-19 to a susceptible individual. However,
<input type="checkbox"/>	-There is very limited evidence available supporting that a person vaccinated against SARS-CoV-2 with any of the currently available vaccines (including those authorised in the EU) is unable to transmit COVID-19 to a susceptible individual. However,
<input checked="" type="checkbox"/>	Other (please specify)
Explanatory note: Option 2 (continuation) "However, we have started to discuss and it is likely that we would only accept a person as "vaccinated" if he/she received a vaccine that is authorized in Europe".	
Option 3 (continuation) -Same continuation than option 2	

<b>1.8.18. Question</b>	
Q64a: Is your country facing challenges around vaccine supply?	
<input checked="" type="checkbox"/>	- Yes
<input type="checkbox"/>	- No

<b>1.8.19. Question</b>	
Q64b: If yes, how has the vaccination roll-out been impacted by issues with vaccine supply?	
<input checked="" type="checkbox"/>	- Suspension of the vaccination campaign in different regions
<input type="checkbox"/>	- The need to make adaptations to priority groups
<input type="checkbox"/>	- Other, please specify



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



<b>1.8.20. Question</b>
Q64c: Please provide details about what is causing the challenges around vaccine supply identified above
delays in our planning due to limited supply
Expected type of value : Text of maximum 1500 characters.

<b>1.8.21. Question</b>
Q65a: Is your country facing any challenges around vaccine roll-out related to logistics and infrastructure?
<input type="checkbox"/> - Storage capacity
<input type="checkbox"/> - Shipping and transshipment (e.g. from distribution hubs to vaccination delivery sites, such as vaccination centres)
<input type="checkbox"/> - Availability of equipment to maintain an adequate cold chain
<input type="checkbox"/> - Optimal management of stock and avoiding expiration of doses
<input type="checkbox"/> - Wastage of doses
<input type="checkbox"/> - Vaccinating outside of target groups to avoid wasting of doses
<input type="checkbox"/> - Managing vaccines with different requirements (regarding adapting logistics, storage and/or administration)

<b>1.8.22. Question</b>
- Q65b: Is your country facing any challenges around vaccine roll-out related to workforce and equipment?
<input type="checkbox"/> - Lack of trained workforce to administer vaccinations
<input type="checkbox"/> - Necessity to train additional staff such as GPs and pharmacists
<input type="checkbox"/> - Poor vaccination acceptance among those administering vaccines
<input type="checkbox"/> -Willingness of staff to vaccinate
<input type="checkbox"/> - Reimbursement issues
<input type="checkbox"/> - Shortages of personal protective equipment to deliver the vaccine
<input checked="" type="checkbox"/> - Shortages of equipment needed for vaccination, such as syringes, including shortage of low dead-space syringes/needles

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



1.8.23. Question	
Q65c: Is your country facing any challenges around vaccine roll-out related to vaccination sites, appointments, and collection of data?	
<input type="checkbox"/>	- Availability of vaccination sites in order to cover the population eligible for vaccination
<input type="checkbox"/>	- The organisation logistics and the running of vaccination centres
<input checked="" type="checkbox"/>	- Locating alternative vaccination sites for future mass vaccination
<input type="checkbox"/>	- Reaching hard to reach populations (such as in rural areas)
<input type="checkbox"/>	- Access of vaccination to vulnerable population groups
<input type="checkbox"/>	- Identifying and contacting target groups for vaccination
<input type="checkbox"/>	- Inefficient booking systems for scheduling people for vaccinations
<input type="checkbox"/>	- Lack of capacity to ensure vaccination time slots are filled and back up plans for those that don't turn up
<input checked="" type="checkbox"/>	- Data from all vaccination centres do not reach you within the agreed timeframe
<input type="checkbox"/>	- Incomplete reporting, but distributed at random in the national territory
<input checked="" type="checkbox"/>	- Incomplete data for some specific population groups
<input type="checkbox"/>	- Data missing on key variables such as vaccine product, dose number, data on dose administered

1.8.24. Question	
Q65e: Other challenges, please specify:	
Expected type of value : Text of maximum 1500 characters.	

1.8.25. Question	
Q65f: If "wastage of doses" selected, what amount of doses are wasted every week on average? How are wasted doses used?	
wastage of doses is relocated to our follow up groups in the national vaccination strategy	
Expected type of value : Text of maximum 1500 characters.	

1.8.26. Question	
Q65g: If "vaccine acceptance among those groups eligible for vaccination" selected, what percentage of the population, on average, is refusing vaccination?	
Expected type of value : Text of maximum 1500 characters.	

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



### 1.8.27. Question

Q65h: If “vaccine acceptance among those groups eligible for vaccination” selected, what percentage of different target groups (i.e. HCW, residents in LTCF, elderly), on average, are refusing vaccination?

Expected type of value : Text of maximum 1500 characters.

### 1.8.28. Question

Q65i: Please briefly provide details about what is causing the challenges around vaccine roll-out identified above.

Limited supply

Expected type of value : Text of maximum 1500 characters.

### 1.8.29. Question

Q66: What measures or solutions have you put in place to mitigate the most important issues in vaccine roll-out identified in your country?

maximum flexibility in roll-out to follow-up groups,

Expected type of value : Text of maximum 1500 characters.

## 2. Questionnaire 2 - Mobility, internal / external borders, tourism, etc.

### 2.1. Public health and life - non-pharmaceutical countermeasures

#### 2.1.1. Question

Q1: Is the usage of a mask mandatory in public?

Yes

No

#### 2.1.2. Question

Q2: If not, is it recommended?

Yes

No

Please describe the measure (including start and end dates) (max. 500 characters):

Free text for Option n° 3

Wearing a mask is mandatory at indoor public places such as the train station or the supermarket, but not while walking outdoors in public.

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



<b>2.1.3. Question</b>	
Q3: Are you requiring physical distancing?	
<input checked="" type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input checked="" type="checkbox"/>	If yes, please briefly describe the measures in place (if available, indicate start and end dates): (max 500 characters)
Free text for Option n° 3	
A physical distance of at least 2 metres is compulsory at all times. Moreover, at home one can only invite one guest per day.	

## 2.2. Travel and borders

<b>2.2.1. Question</b>	
Q4: In order to ensure a proper coordinated approach between all Member States (and the Commission), are you ready to try to give prior notification through the IPCR of all new and planned measures, particularly the lifting of restrictions having implications for cross border tourism and travel, if possible at least 7 days before they enter into force?	
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	Please qualify your answer if relevant: (max 500 characters)
Free text for Option n° 3	

<b>2.2.2. Question</b>	
Q5: Do you advise against travel – essential or non-essential – to any risk areas as per national definition?	
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	If yes, please describe the practice, and indicate the start and end date of the measure (if available): (max 500 characters)
Free text for Option n° 3	

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



2.2.3. Question	
Q6: Do you apply restrictions to movement WITHIN your country?	
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	If yes, please describe the practice, and indicate the start and end date of the measure (if available): (max 500 characters)
Free text for Option n° 3	

2.2.4. Question	
Q7: Do you apply restrictions to travellers departing FROM or entering INTO your country from other EU / EEA Member States?	
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	If yes, please describe which restrictions apply to which countries, on which basis you justify such restrictions taking into account the principle of proportionality and non-discrimination, indicate start and end date of the measure (if available):
Free text for Option n° 3	

2.2.5. Question	
Q8: Do you require a medical certificate or negative test upon entry?	
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	If yes, please describe the practice (e.g. type of test / certificate), and indicate the start and end date of the measure (if available): (max 500 characters)
Free text for Option n° 3	

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)





<b>2.2.6. Question</b>	
Q9: Do you require people entering the country to self-quarantine?	
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	If yes, for how long? Please describe the practice, and indicate the start and end date of the measure (if available): (max 500 characters)
Free text for Option n° 3	

<b>2.2.7. Question</b>	
Q10: Do you apply restrictions to third-country nationals coming from outside the EU / EEA?	
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	If yes, please describe the practice, and indicate the start and end date of the measure (if available): (max 500 characters)
Free text for Option n° 3	

<b>2.2.8. Question</b>	
Q11: Have you made or are you planning any other bilateral arrangements with other Member States to permit the restoration of cross border travel and tourism just with them?	
Expected type of value : Text of maximum 1200 characters.	
Explanatory note: Please note that as stated in the Commission's Communication on phased and coordinated approach for restoring freedom of movement and lifting internal border controls, where a Member State decides to allow travel into its territory or to specific regions and areas within its territory, it should do so in a non-discriminatory manner – allowing travel from all regions or countries in the EU with similar epidemiological situations.	

### 2.3. Tourist services

<b>2.3.1. Question</b>	
Q12: Do you have or are you planning a website (or other form of information provision) for tourists to inform them of COVID-19 tourism related topics/measures?	
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



<b>2.3.2. Question</b>
Q12a: What is the link? (max 100 characters)
Expected type of value : Text of maximum 200 characters.

<b>2.3.3. Question</b>
Q12b: Is it or going to be available in different languages? If so, which? (max 250 characters)
Expected type of value : Text of maximum 1500 characters.

<b>2.3.4. Question</b>
Q13: Do you have remaining COVID-19 related restrictions on the provision of services applying at national or sub-national / regional level and have you announced a timetable for lifting such restrictions?
<input type="checkbox"/> Yes
<input type="checkbox"/> No

<b>2.3.5. Question</b>
Q14a: Are non-essential shops (i.e. shops not selling food or medicine) accessible?
<input type="checkbox"/> Yes
<input type="checkbox"/> No
<input type="checkbox"/> If no, please describe the practice, and indicate the start and end date of the restriction (if available); (max 500 characters)
Free text for Option n° 3

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)





<b>2.3.6. Question</b>	
Q14b: Is tourism accommodation available (hotels, B&B, campsites, short-stay rentals)?	
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	If no, please describe the practice, and indicate the start and end date of the restriction (if available): (max 900 characters)
Free text for Option n° 3	

<b>2.3.7. Question</b>	
Q14c: Are restaurants open?	
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	If no, please describe the practice, and indicate the start and end date of the restriction (if available): (max 500 characters)
Free text for Option n° 3	

<b>2.3.8. Question</b>	
Q14d: Are bars and cafes open?	
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	If no, please describe the practice, and indicate the start and end date of the restriction (if available): (max 500 characters)
Free text for Option n° 3	





<b>2.3.9. Question</b>	
Q14e: Are beaches and tourist areas openly accessible?	
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	If no, please describe the practice, and indicate the start and end date of the restriction (if available): (max 500 characters)
Free text for Option n° 3	

<b>2.3.10. Question</b>	
Q14f: Are museums and heritage sites open?	
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	If no, please describe the practice, and indicate the start and end date of the restriction (if available): (max 500 characters)
Free text for Option n° 3	

<b>2.3.11. Question</b>	
Q14g: Are places of worship accessible?	
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	If no, please describe the practice, and indicate the start and end date of the restriction (if available): (max 500 characters)
Free text for Option n° 3	





<b>2.3.12. Question</b>	
Q14h: Are personal care services available?	
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	If no, please describe the practice, and indicate the start and end date of the restriction (if available): (max 500 characters)
Free text for Option n° 3	

<b>2.3.13. Question</b>	
Q15: Are there specific health safety protocols for tourism services and tourists in place or planned?	
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No

<b>2.3.14. Question</b>	
Q15a: If yes, please add the link where the protocols are available and indicate the languages in which they are available. (max 1500 characters)	
Expected type of value : Text of maximum 1500 characters.	

<b>2.3.15. Question</b>	
Q15b: If planned, for which date and for which categories of tourism services? (max 1500 characters)	
Expected type of value : Text of maximum 1500 characters.	

<b>2.3.16. Question</b>	
Q16: What measures are you planning to protect tourism workers (e.g. PPE) and will you require them for cross border tourism workers (outgoing and incoming)? Please specify measures by category of tourism service as applicable.	
Expected type of value : Text of maximum 1500 characters.	



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



### 2.3.17. Question

Q17: Are you planning arrangements for “closed door” (i.e. organised coach tours without intermediate pickup) tourism packages for your citizens or incoming tourists?

Expected type of value : Text of maximum 1500 characters.

## 2.4. Transport

### 2.4.1. Question

Q18: Do you have or are you planning a website for transport users to inform them of COVID-19 transport related topics (separate from anything planned under Q13)?

Yes

No

### 2.4.2. Question

Q18a: What is the link? (max 100 characters)

Expected type of value : Text of maximum 200 characters.

### 2.4.3. Question

Q18b: Is it or going to be available in different languages? If so, which? (max 250 characters)

Expected type of value : Text of maximum 1500 characters.

### 2.4.4. Question

Q19: What measures do you have or are you planning to safeguard the movement of freight throughout the EU to maintain the maximum 15 minutes delay for freight in the Green Lanes at the border if restrictions on private passenger traffic across borders are lifted and you have additional pressures on border crossing points? (max 1500 characters)

Expected type of value : Text of maximum 1500 characters.

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)



**2.4.5. Question**

Q20: Above and beyond any general requirements for entry and exit (see questions on travel and borders), what restrictions do you have in place for passengers planning to cross borders (internal or external) on the following modes of transport, to/from all or specific countries (if so, which countries?), and what plans do you have for lifting them, e.g. in stages/phases? Please specify for each case (and sub-mode, if there is other relevant information, e.g. "business aviation").

Expected type of value : Text of maximum 1500 characters.

**2.4.6. Question**

Q20a: Car or motorcycle: (max 900 characters)

Expected type of value : Text of maximum 1200 characters.

**2.4.7. Question**

Q20b: Train: (max 900 characters)

Expected type of value : Text of maximum 1200 characters.

**2.4.8. Question**

Q20c: Bus and coach: (max 900 characters)

Expected type of value : Text of maximum 1200 characters.

**2.4.9. Question**

Q20d: Waterborne: (max 900 characters)

Expected type of value : Text of maximum 1200 characters.



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



<b>2.4.10. Question</b>
Q20e: Plane: (max 900 characters)
Expected type of value : Text of maximum 1200 characters.

<b>2.4.11. Question</b>
Q20f: Other: (max 900 characters)
Expected type of value : Text of maximum 1200 characters.

<b>2.4.12. Question</b>
Q21: Do you plan any particular measures for passengers transiting your country?
<input type="checkbox"/> Yes
<input type="checkbox"/> No
<input type="checkbox"/> If yes, please specify: (max 500 characters)
Free text for Option n° 3

<b>2.4.13. Question</b>
Q22: Do you have any continued controls on movement of essential workers, such as transport workers (please specify), and what plans do you have to lift such controls? (max 900 characters)
Expected type of value : Text of maximum 1500 characters.

<b>2.4.14. Question</b>
Q23: What measures are you planning to protect transport workers (e.g. PPE) and will you require them for cross border transport workers (outgoing and incoming)? Please specify measures by transport mode as necessary. (max 900 characters)
Expected type of value : Text of maximum 1500 characters.

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)



**2.4.15. Question**

Q24: How do you ensure the issuing / extending of short stay visas to essential workers from non-EU countries pending the full resumption of full operations in your consulates abroad? (max 900 characters)

Expected type of value : Text of maximum 1500 characters.

**2.4.16. Question**

Q25: What measures are in place to protect passengers on all collective forms of transport? (recommendations 28-36 and 41 of the COVID-19: Guidelines on the progressive restoration of transport services and connectivity (please specify, if possible with start and end dates) (max 900 characters)

Expected type of value : Text of maximum 1500 characters.

**2.4.17. Question**

Q26: Are you planning or do you plan to provide incentives (e.g. lump sums, loans, scrapping schemes) for the purchase or upgrade of transport means? (e.g. to safer and more sustainable transport options in light of COVID-19?

Yes

No

If yes, please specify: (max 500 characters)

Free text for Option n° 3

**2.4.18. Question**

Q27: Are you developing/implementing new technology solutions and/or other innovative measures at borders to address public health risks associated with movement of people across borders?

Yes

No

If yes, please specify:

Free text for Option n° 3



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



#### 2.4.19. Question

Q28: Are you planning to offer incentives/assistance to transport operators to enable them to adhere to public health guidelines and/or to adapt their services to new guidelines? (max 900 characters)

Expected type of value : Text of maximum 1500 characters.

#### 2.4.20. Question

Q29: The Communication on Tourism and Transport sets out that the Commission's Joint Research Centre and the ECDC, in cooperation with Member States, will continuously maintain a map of the level of Covid-19 transmission at sub-national level. What is the method that you prefer to communicate the level of transmission at subnational level (Rti) for your regions or provinces?

- a) Excel file via e-mail
- b) Json file via e-mail
- c) Excel file uploaded to a site
- d) Json file uploaded to a site
- e) Compilation of a web form online
- f) Other (please specify):

Free text for Option n° 6

Explanatory note: This question will not be needed after the map is launched.

#### 2.4.21. Question

Q30: Is there any other information or other measures you wish to include? (max 900 characters)

Expected type of value : Text of maximum 1500 characters.

### 2.5. Difficulties with internal or external border restriction concerning the transport of goods

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)





<b>2.5.1. Question</b>	
Q31: Has your country experienced difficulties with clearance of goods at external borders (notably medicine, PPE)?	
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	Please specify:
Free text for Option n° 3	

### 3. Questionnaire 3 - Socio-economy

#### 3.1. Socio-economy

##### 3.1.1. Question

Q1: Are there any activities in place to monitor / model economic / social impacts? How are these included in the exit strategy?

Expected type of value : Text of maximum 1500 characters.

#### 3.2. Sectors and supply chains most affected (e.g. aviation, tourism, agriculture)

##### 3.2.1. Question

Q2: Has your country noted drops in production? In which sectors? How has it impacted supply chains?

Expected type of value : Text of maximum 1500 characters.

##### 3.2.2. Question

Q3: Has your country noted drops in demand? In which sectors?

Expected type of value : Text of maximum 1500 characters.



**3.2.3. Question**

Q4: Has your country noted effects on exports? In which sectors?

Expected type of value : Text of maximum 1500 characters.

**3.2.4. Question**

Q5: Can your country report on downsizing of operations (or even ceasing of activity)? In this respect, please provide information you might have available on e.g.:

- 1) The way businesses are affected by the outbreak.
- 2) Consequent measures possibly undertaken in terms of employment and the number of workers affected.
- 3) Sectors concerned and/or specific example.

Expected type of value : Text of maximum 1500 characters.

**3.2.5. Question**

Q6: If any sector have reported any disruption or risk of disruption of its supply chain (intra-EU or extra-EU supply chains), could you please share with us this information? In which sectors are these disruptions still severe now? In this respect, please provide information you might have available on:

- 1) Shortages of raw materials and other key input for internal production chains.
- 2) Current dependency on extra-EU suppliers for raw materials and key input.

Expected type of value : Text of maximum 1500 characters.

**3.2.6. Question**

Q7: For the particular case of the supply of personal protective equipment: what is the situation in your country? Which are the measures that have been implemented to facilitate and encourage the production?

Expected type of value : Text of maximum 1500 characters.

**3.2.7. Question**

Q8: Which are the biggest issues that companies, that are now restarting their activities, are facing in your country?

Expected type of value : Text of maximum 1500 characters.



**3.3. Measures taken to counter the downturn (fiscal, state aid...)****3.3.1. Question**

Q9: In general, what measures (e.g. ta-related measures such as tax administration or tax deferrals, borrower- and lender-based measures in the financial sector, labour market measures such as employment subsidies and/or short-term working arrangements, state aid) have been taken to counter the downturn of this crisis?

Expected type of value : Text of maximum 1500 characters.

**3.3.2. Question**

Q10: What measures (e.g. public capital investment or human capital (skills and training) investment, subsidies/support to Businesses) are planned and/or have already been implemented to sustain the recovery of the economy to lift up the economy once the crisis is over?

Expected type of value : Text of maximum 1500 characters.

**3.4. Estimate of the impact****3.4.1. Question**

Q11: What is the estimated impact on annual growth?

Expected type of value : Text of maximum 1500 characters.

**3.4.2. Question**

Q12: What is the estimated impact on national labour market?

Expected type of value : Text of maximum 1500 characters.

**3.4.3. Question**

Q:13: If still relevant, what is the impact on and measures related to temporary / seasonal EU workers working in other MS?

Expected type of value : Text of maximum 1500 characters.



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



#### 3.4.4. Question

Q14: What is the outlook of impact on agricultures and other critical sectors (power, security), including business continuity for critical infrastructure (e.g. power utilities, in particular nuclear power plants)?

Expected type of value : Text of maximum 1500 characters.

#### 3.4.5. Question

Q15: Has your country faced or expects challenges with essential services such as Internet provision?

Expected type of value : Text of maximum 1500 characters.

### 3.5. Support to SME

#### 3.5.1. Question

Q16: To support SMEs, has your country implemented financial guarantees for businesses?

Yes

No

Please specify:

Free text for Option n° 3

#### 3.5.2. Question

Q17: To support SMEs, has your country implemented grants and financial transfers to businesses including wage subsidies?

Yes

No

Please specify:

Free text for Option n° 3

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



### 3.5.3. Question

Q18: To support SMEs, what new (in the last month) national measures have been implemented with regards to loans?

Expected type of value : Text of maximum 1500 characters.

### 3.5.4. Question

Q19: To support SMEs, what new (in the last month) national measures have been implemented with regards to administrative burden reduction / simplification, e.g. tax deferrals?

Expected type of value : Text of maximum 1500 characters.

### 3.5.5. Question

Q20: To support SMEs, what new (in the last month) national measures have been implemented with regards to equity-support measures, especially for start-ups and scale-ups?

Expected type of value : Text of maximum 1500 characters.

### 3.5.6. Question

Q21: To what extent the above measures also apply for businesses more broadly and/or larger companies?

Yes

No

## 4. Questionnaire 4: Additional questions on next waves

### 4.1. Question

Q2: What is your country's strategy for potential next waves / re-escalation?

Expected type of value : Text of maximum 1500 characters.

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



#### 4.2. Question

Q3: Has your country identified major issues and associated impact caused by differences in the timing or extent of de-escalation / re-escalation measures taken across the EU/EEA and UK?

Yes

No

Please specify

Free text for Option n° 3

#### 4.3. Question

Q4: Has your country been facing problems with enforcement of or adherence to control measures?

Yes

No

Please clarify, e.g., increased number of tourists, repeated mass gatherings, opening hours, social distancing, personal protection, mask wearing, other

Free text for Option n° 3

#### 4.4. Question

Q5: Has your country witnessed any gaps in preparedness?

Yes

No

Please specify

Free text for Option n° 3

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



#### 4.5. Question

Q6: Does your country have contingency plans for next waves? E.g., contingency plans in schools etc.

Yes

No

Please specify

Free text for Option n° 3

#### 4.6. Question

Q7: Has your country identified any needs for guidelines? If yes, in which area?

Yes

No

Please specify

Free text for Option n° 3

### 5. Questionnaire 5 - Other issues

#### 5.1. Disinformation

##### 5.1.1. Question

Q1: Has your country witnessed increased and organized disinformation activities in the media / online?

Yes

No

Please specify which type of behavior is at stake:

Free text for Option n° 3

#### 5.2. Cyber attacks

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)



Please save this file to your device before filling it in. Otherwise, the inserted information can be lost.



<b>5.2.1. Question</b>	
Q3: Has your country noted cyber-attacks in the context of COVID-19?	
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
<input type="checkbox"/>	Please detail the event and the response:
Free text for Option n° 3	

### 5.3. Questions in relation to European Citizens Initiatives – COVID-19 extension of collection periods of initiatives

<b>5.3.1. Question</b>	
Q5: Does your country apply COVID-19 containment measures within your country? COVID-19 containment (also referred to as confinement) measures refer here to a set of measures that prohibit citizens from moving around freely	
<input type="checkbox"/>	YES
<input type="checkbox"/>	NO
<input type="checkbox"/>	NO, but with exceptions at local/regional level; please provide the approximate percentage of the country's population affected...%
Free text for Option n° 3	
<p>Explanatory note: Due to the COVID-19 pandemic, organisers of citizens' initiatives find it difficult to collect paper statements of support and to do local campaigning. Under Regulation (EU) 2020/1042, the Commission, therefore, is allowed to (further) extend the collection periods under specific conditions.</p> <p>To allow the Commission to assess if an extension is justified, Member States shall inform the Commission on the measures that they apply in response to the COVID-19 pandemic or a new outbreak.</p>	

Downloaded from IPCR Web Platform by [redacted] on 26-03-2021 09:03 (CET)





<b>5.3.2. Question</b>	
Q6: If and to what extent are public spaces (including parks and other recreational spaces, public service institutions, shopping areas and market places) open to the public?	
<input type="checkbox"/>	Fully open
<input type="checkbox"/>	Partially open
<input type="checkbox"/>	Closed
Free text for Option n° 3	
<p>Explanatory note: Questions in relation to European Citizens Initiatives – COVID-19 extension of collection periods of initiatives</p> <p>Due to the COVID-19 pandemic, organisers of citizens' initiatives find it difficult to collect paper statements of support and to do local campaigning. Under Regulation (EU) 2020/1042, the Commission, therefore, is allowed to (further) extend the collection periods under specific conditions.</p> <p>To allow the Commission to assess if an extension is justified, Member States shall inform</p>	

<b>5.3.3. Question</b>	
Q7: If and to what extent are meetings, public or private gatherings and events allowed? Please indicate the level of capacity restrictions, by indicating the number of maximum people allowed (covering both inside and outside, taking the highest number where applicable).	
<input type="checkbox"/>	More than 1000 persons (or no restrictions)
<input type="checkbox"/>	Between 500 and 1000 persons
<input type="checkbox"/>	Between 200 and 500 persons
<input type="checkbox"/>	Up to 100 - 200 persons
<input type="checkbox"/>	Not allowed, or only up to 10-20 persons
<input type="checkbox"/>	Please provide details
Free text for Option n° 6	
<p>Explanatory note: Questions in relation to European Citizens Initiatives – COVID-19 extension of collection periods of initiatives</p> <p>Due to the COVID-19 pandemic, organisers of citizens' initiatives find it difficult to collect paper statements of support and to do local campaigning. Under Regulation (EU) 2020/1042, the Commission, therefore, is allowed to (further) extend the collection periods under specific conditions.</p> <p>To allow the Commission to assess if an extension is justified, Member States shall inform</p>	

